Q-omics provides the consensus-scored HOXC-AS2 profile across patient tissues and cancer cell-line models. HOXC-AS2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HOXC-AS2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, HOXC-AS2 RNA expression shows 14,140 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, HNSC, and KIRP as cancer lineages where HOXC-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXC-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXC-AS2 survival associations across molecular data types. HOXC-AS2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXC-AS2 RNA expression–survival associations across cancer types. High HOXC-AS2 expression shows unfavorable associations in ACC, LGG and GBM, but favorable associations in KIRP, SKCM and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HOXC-AS2 RNA expression.
This table summarizes HOXC-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXC-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXC-AS2 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, STAD, BLCA and LUSC. The HNSC box plot shows higher HOXC-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.920, t-test p < 0.001).
This table shows molecular features associated with HOXC-AS2 in patient tissues and cancer cell lines. In patient samples, HOXC-AS2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
